Results 21 to 30 of about 17,429 (49)

FEATURES OF CEREBRAL HEMODYNAMICS AND MANIFESTATIONS OF HEPATIC ENCEPHALOPATHY IN CIRRHOSIS OF VIRAL ETIOLOGY AT DIFFERENT COMPENSATION STAGES WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION

Рациональная фармакотерапия в кардиологии, 2017
Aim. To study the features of the parameters of cerebral hemodynamics in extra and intracranial regions in viral hepatic cirrhosis A, B, C classes according to Child-Pugh with different serum levels of interleukin-2, interleukin-6 and tumor necrosis ...
V. E. Kulikov, T. A. Emelina, O. G. Kazakova, K. V. Nikolaevа, M. E. Hapman, M. A. Tonеeva   +5 more
doaj   +1 more source

Evaluation of Salivary Interleukin 2 (IL-2) and Interleukin 12(IL-12) in Recurrent Aphthous Stomatitis

Ibn Al-Haitham Journal for Pure and Applied Sciences
Recurrent aphthous stomatitis (RAS) is  a common kind of excruciating mouth mucosal disease. Despite their high prevalence, etiopathogenesis remains unclear.
Sura Farhan Saeed, Zainab Abduljabar Aldhaher   +1 more
doaj   +1 more source

Interleukin-10 inhibits the production of inflammatory cytokines by antigen-stimulated mononuclear cells from asthmatic patients

Allergology International, 2000
Bronchial asthma, characterized by chronic airway inflammation, involves many inflammatory cytokines. Interleukin (IL)-10 is a potent inhibitor of cytokine synthesis.
Toshiya Takahashi, Ken-ichi Maeda, Yoichi Nakamura, Yoshio Okano, Ning Ge, Saburo Sone   +5 more
doaj   +1 more source

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

mAbs, 2021
Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα.
Inja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, Tapan K Nayak, Linda Fahrni, Ralf J. Hosse, Danny Gerrits, Edwin J. W. Geven, Johannes Sam, Sabine Lang, Esther Bommer, Virginie Steinhart, Elisabeth Husar, Sara Colombetti, Erwin Van Puijenbroek, Markus Neubauer, J. Mark Cline, Pradeep K. Garg, Gregory Dugan, Federica Cavallo, Gonzalo Acuna, Jehad Charo, Volker Teichgräber, Stefan Evers, Otto C. Boerman, Marina Bacac, Ekkehard Moessner, Pablo Umaña, Christian Klein   +28 more
doaj   +1 more source

The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery

Life, 2020
(1) Background: The intravesical instillation of interleukin-2 (IL-2) has been shown to be very well tolerated and promising in patients with bladder malignancies.
Lisa Schmitz, Belinda Berdien, Edith Huland, Petra Dase, Karin Beutel, Margit Fisch, Oliver Engel   +6 more
doaj   +1 more source

A versatile design platform for glycoengineering therapeutic antibodies

mAbs, 2022
Manipulation of glycosylation patterns, i.e., glycoengineering, is incorporated in the therapeutic antibody development workflow to ensure clinical safety, and this approach has also been used to modulate the biological activities, functions, or ...
Seth D. Ludwig, Zachary J. Bernstein, Christian Agatemor, Kris Dammen-Brower, Jeffrey Ruffolo, Jonah M. Rosas, Jeremy D. Post, Robert N. Cole, Kevin J. Yarema, Jamie B. Spangler   +9 more
doaj   +1 more source

Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma

OncoImmunology, 2022
Pancreatic ductal adenocarcinoma (PDA) is usually unresponsive to immunotherapeutic approaches. However, tertiary lymphoid structures (TLS) are associated with favorable patient outcomes in PDA.
Azaz Ahmed, Sophia Köhler, Rosa Klotz, Nathalia Giese, Thilo Hackert, Christoph Springfeld, Inka Zörnig, Dirk Jäger, Niels Halama   +8 more
doaj   +1 more source

Structure-function relationships for the interleukin 2 receptor system

Memorias do Instituto Oswaldo Cruz, 1987
Receptors for interleukin 2 (IL-2) esit in at least three forms which differ in their subunit compositio, their affinity for ligand and their ability to mediate a cellular reponse.
Richard J. Robb
doaj   +1 more source

Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia

Cells, 2020
Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary ...
Dipnarine Maharaj, Gayathri Srinivasan, Maria M. Abreu, Meng-Wei Ko, Anahid Jewett, Jacqueline Gouvea   +5 more
doaj   +1 more source

Better Identification of Cognitive Decline With Interleukin-2 Than With Amyloid and Tau Protein Biomarkers in Amnestic Mild Cognitive Impairment

Frontiers in Aging Neuroscience, 2021
The rate of cognitive decline among patients with amnestic mild cognitive impairment (aMCI) varies, and it is thus crucial to accurately predict the probability of cognitive deterioration in patients with MCI.
Chih-Sung Liang, Chih-Sung Liang, Chia-Lin Tsai, Guan-Yu Lin, Jiunn-Tay Lee, Yu-Kai Lin, Yu-Kai Lin, Che-Sheng Chu, Che-Sheng Chu, Yueh-Feng Sung, Chia-Kuang Tsai, Ta-Chuan Yeh, Hsuan-Te Chu, Ming-Wei Su, Fu-Chi Yang, Fu-Chi Yang   +15 more
doaj   +1 more source